Evrys Bio at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Evrys Bio brings 3 presentations to IDWeek 2026 in Washington. Its program centres on antivirals that target the patient's own cells rather than the virus. One candidate shows activity across herpes, polyoma, hepatitis and respiratory viruses, suggesting broad prophylaxis, and separate work proposes that same human enzyme as a route to a functional cure of chronic hepatitis B.
| Organization | IDWeek 2026 Attendance |
|---|---|
Evrys Bio Doylestown, PA | |
Biotech developing host-targeted small-molecule antivirals that act on the human enzyme sirtuin 2, starting with transplant-related viral infections. | Poster Thu Oct 22 12:15pm–1:30pm Host-Targeted Antiviral EV-100 Is Broadly Effective Against Four Major Classes of Opportunistic Viruses (Herpes, Polyoma-, Hepatic, and Respiratory Viruses) and May Therefore Be Suitable for Pan-Viral Prophylaxis or Preemptive Use Talk Fri Oct 23 12:30pm–12:35pm Host-Targeted Antiviral EV-100 Is Broadly Effective Against Four Major Classes of Opportunistic Viruses (Herpes, Polyoma-, Hepatic, and Respiratory Viruses) and May Therefore Be Suitable for Pan-Viral Prophylaxis or Preemptive Use Antimicrobials, resistance and stewardshipTransplant and immunocompromised hosts Poster Sat Oct 24 12:15pm–1:30pm Human Sirtuin 2 (SIRT2) is an Epigenetic Small-Molecule Drug-Target for Functional Cure of Chronic Hepatitis B |
Instantly find 20 buyers from Evrys Bio
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction